Exenatide
Summary
"Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that acts as an ‘incretin mimetic’. It exhibits many of the same glucoregulatory or glucose-lowering actions as GLP-1 (a naturally occurring incretin hormone) and helps to control blood glucose levels."
Risk. The use of amino acids, proteins, and peptides is considered not to pose any environmental risk.
This summary information comes from fass.se and assessment report.
Detailed information
Assessment report
Assessment report for Bydureon (exenatide) 28 June 2018, EMA/700805/2018.
"No environmental risk assessment has been performed. This is acceptable and in line with the CHMP guideline which states that peptides are exempted from such assessment."
Fass environmental information
Fass environmental information for Bydureon from AstraZeneca (retrieved on 2025-06-30).
The use of amino acids, proteins and peptides is not considered to have any environmental impact.
Detailed information
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
Author: Health and Medical Care Administration, Region Stockholm